Abionyx Pharma Announces a Capital Increase of €18.7 Million at €2.65 per Share

Capital Increase with Preferential Subscription and Guarantees

The capital increase, with a gross amount of €18.7 million, will be carried out at a price of €2.65 per new share, with a ratio of 1 new share for every 5 existing shares. The subscription period will extend from June 2 to June 15, 2026. The operation benefits from guarantees amounting to €18.69 million from 26 investors, including new financial partner Fenja Capital, a Danish fund specializing in the health and biotech sectors.

Subscription rights will be negotiable on the stock exchange from May 29 to June 11, 2026. Each existing shareholder will receive one subscription right per share held as of June 1, 2026. The theoretical value of the right is established at €0.1375, calculated based on the closing price of May 26, 2026, of €3.475. The subscription price of €2.65 represents a discount of 20.6% compared to the ex-right value.

Bond Financing to Supplement Cash Reserves

In parallel, Abionyx has entered into an agreement with Fenja Capital for a bond financing of up to €14 million in two tranches. The first tranche of €10 million is expected to be drawn on June 18, 2026 (provided that the capital increase generates at least €14 million gross), while the second tranche of €4 million could be mobilized during the last quarter of 2026, under certain liquidity and market capitalization conditions.

The bonds bear interest at the three-month Euribor rate (floor of 2%) plus a margin of 3% per annum. They mature on May 26, 2028, with an option to extend until November 26, 2028. Fenja also receives free-of-charge warrants, exercisable over five years, corresponding to a dilution of 5% and granting access to 2.24 million shares at a price of €3.71.